Add-on Acquisition • Life Science

Sobi Acquires CTI BioPharma

On May 10, 2023, Sobi acquired life science company CTI BioPharma for 1.7B USD

Acquisition Context

This is Sobi’s 3rd transaction in the Life Science sector.
This is Sobi’s largest (disclosed) transaction.
This is Sobi’s 2nd transaction in the United States.
This is Sobi’s 1st transaction in Washington.

Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	May 10, 2023
Target	CTI BioPharma
Sector	Life Science
Buyer(s)	Sobi
Deal Type	Add-on Acquisition
Deal Value	1.7B USD

Target Company

CTI BioPharma

Seattle, Washington, United States

CTI is a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI BioPharma was founded in 1991 and is based in Seattle, Washington.

Explore More Deals

Browse All 215,156 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

Sobi

Stockholm   , Sweden

Category	Company
Founded	1939
Sector	Life Science
Employees	1,895
Revenue	26.0B SEK (2024)

DESCRIPTION

Sobi is an integrated biopharmaceutical company with an international market presence, developing and commercializing pharmaceuticals for patients with rare diseases. Sobi was founded in 1939 and is headquartered in Solna, Sweden.

Deal Context for Buyer	#
Overall	4 of 4
Sector: Life Science	3 of 3
Type: Add-on Acquisition	4 of 4
State: Washington	1 of 1
Country: United States	2 of 2
Year: 2023	1 of 1
Size (of disclosed)	1 of 3

PREVIOUS DEAL

DATE	TARGET	DEAL TYPE	VALUE
2019-09-30	Dova Pharmaceuticals Durham, North Carolina, United States Dova Pharmaceuticals, Inc. is a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases where there is a high unmet medical need. Dova Pharmaceuticals was founded in 2016 and is headquartered in Durham, North Carolina.	Buy	$915M

DATE

TARGET

DEAL TYPE

VALUE

2019-09-30

Dova Pharmaceuticals

Durham, North Carolina, United States

Dova Pharmaceuticals, Inc. is a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases where there is a high unmet medical need. Dova Pharmaceuticals was founded in 2016 and is headquartered in Durham, North Carolina.

Buy

$915M

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - Washington M&A - United States M&A - 2023 M&A